| View Slide
Show
click here
|
Dr. Michael T. Chin
is interested in the genetic regulation of cardiovascular development and the
role of developmental mechanisms in adult cardiovascular disease. He has
previously identified two novel bHLH transcription factors, CHF1 and CHF2, which
are expressed predominantly in the developing cardiovascular system. CHF1 is
expressed primarily in the developing ventricle and arterial vasculature, while
CHF2 is expressed primarily in the developing atria. Dr. Chin’s work has
demonstrated that these proteins function as transcriptional repressors and are
important regulators of cardiovascular development, cardiac hypertrophy and the
development of occlusive vascular disease. Currently, his laboratory has three
major areas of interest: 1. to determine the molecular mechanisms by which CHF1
regulates the development of the interventricular septum, myocardium and
vasculature; 2. to determine the molecular mechanisms by which CHF1 affects the
smooth muscle proliferative response after vascular injury; and 3. to determine
the molecular mechanisms by which CHF1 regulates the myocardial response to
hypertrophic stimuli and the subsequent progression to heart failure. Ongoing
projects within the laboratory include generation of CHF1 conditional knockout
mice, assessing these mice for developmental phenotypes, testing of these mice
in various models of vascular injury, angiogenesis and hypertrophy, and
isolation and characterization of primary endocardial cushion, cardiac myocyte,
vascular smooth muscle and endothelial cells from these mice for in vitro
assessment of cell function and molecular phenotype. We are also using these in
vitro assays to test the ability of small molecules to rescue aspects of the
CHF1 null phenotype. These studies should further our understanding of
cardiovascular development and its relationship to adult cardiovascular
disease.
Sun J, Kamei CN, Layne MD,
Jain MK, Liao JK, Lee M-E, Chin MT. Regulation of myogenic terminal
differentiation by the hairy-related transcription factor CHF2. J Biol Chem
2001;276:18591-18596.
Sakata Y, Kamei CN,
Nakagami H, Bronson R, Liao JK, Chin MT. Ventricular septal defects and
cardiomyopathy in mice lacking the transcription factor CHF1/Hey2. Proc. Natl.
Acad. Sci. USA 2002; 99: 16197-16202.
Sakata Y, Xiang F, Chen Z,
Kiriyama Y, Kamei CN, Simon DI and Chin MT. Transcription factor CHF1/Hey2
regulates neointimal formation in vivo and vascular smooth muscle proliferation
and migration in vitro. Arterioscler Thromb Vasc Biol 2004; 24: 2069-2074.
Sakata Y, Koibuchi N,
Xiang F, Youngblood JM, Kamei CN and Chin MT. The Spectrum of Cardiovascular
Anomalies in CHF1/Hey2 Deficient Mice Reveals Roles in Endocardial Cushion,
Myocardial and Vascular Maturation. J. Mol. Cell. Cardiol. 2006; 40: 267-273.
Xiang F, Sakata Y,Cui L,
Youngblood JM, Nakagami H, Liao JK, Liao R and Chin MT. Transcription factor
CHF1/Hey2 suppresses cardiac hypertrophy through an inhibitory interaction with
GATA4. Am. J. Physiol. Heart Circ. Physiol. 2006; 290: H1997-H2006.
Koibuchi N and Chin MT.
CHF/Hey2 plays a pivotal role in left ventricular maturation through suppression
of ectopic atrial gene expression. Circulation Research, in press, 2007.
Shirvani S,
Mookanamparambil L, Ramoni MF and Chin MT. Transcription factor CHF1/Hey2
regulates the global transcriptional response to platelet-derived growth factor
in vascular smooth muscle cells. Physiological Genomics, in press, 2007.
|